-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Longeveron (NASDAQ:LGVN) Vs. VG Life Sciences (OTCMKTS:VGLS) Head to Head Review
Longeveron (NASDAQ:LGVN) Vs. VG Life Sciences (OTCMKTS:VGLS) Head to Head Review
VG Life Sciences (OTCMKTS:VGLS – Get Rating) and Longeveron (NASDAQ:LGVN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.
Profitability
This table compares VG Life Sciences and Longeveron's net margins, return on equity and return on assets.
Get VG Life Sciences alerts:Net Margins | Return on Equity | Return on Assets | |
VG Life Sciences | N/A | N/A | N/A |
Longeveron | -1,408.17% | -58.68% | -49.93% |
Risk & Volatility
VG Life Sciences has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for VG Life Sciences and Longeveron, as reported by MarketBeat.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
VG Life Sciences | 0 | 0 | 0 | 0 | N/A |
Longeveron | 0 | 0 | 2 | 0 | 3.00 |
Longeveron has a consensus target price of $13.25, suggesting a potential upside of 231.25%.
Institutional and Insider Ownership
2.1% of Longeveron shares are owned by institutional investors. 41.6% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares VG Life Sciences and Longeveron's gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
VG Life Sciences | N/A | N/A | N/A | N/A | N/A |
Longeveron | $1.31 million | 64.09 | -$17.05 million | ($0.89) | -4.49 |
VG Life Sciences has higher earnings, but lower revenue than Longeveron.
About VG Life Sciences
(Get Rating)
VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.
About Longeveron
(Get Rating)
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Receive News & Ratings for VG Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VG Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
VG Life Sciences (OTCMKTS:VGLS – Get Rating) and Longeveron (NASDAQ:LGVN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.
VG生命科學(場外交易代碼:VGLS-GET評級)和朗格韋龍(納斯達克:LGVN-GET評級)都是小盤醫療公司,但哪隻股票更好?我們將根據兩家公司的估值、收益、分析師建議、機構所有權、股息、風險和盈利能力等方面的實力進行比較。
Profitability
盈利能力
This table compares VG Life Sciences and Longeveron's net margins, return on equity and return on assets.
此表比較了VG Life Science和Longeveron的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
VG Life Sciences | N/A | N/A | N/A |
Longeveron | -1,408.17% | -58.68% | -49.93% |
淨利潤率 | 股本回報率 | 資產回報率 | |
VG生命科學 | 不適用 | 不適用 | 不適用 |
龍威龍 | -1,408.17% | -58.68% | -49.93% |
Risk & Volatility
風險與波動性
VG Life Sciences has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
VG生命科學的貝塔係數為1.83,這意味着其股價的波動性比標準普爾500指數高出83%。相比之下,Longeveron的貝塔係數為0.65,這意味着其股價的波動性比標準普爾500指數低35%。
Analyst Ratings
分析師評級
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
VG Life Sciences | 0 | 0 | 0 | 0 | N/A |
Longeveron | 0 | 0 | 2 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
VG生命科學 | 0 | 0 | 0 | 0 | 不適用 |
龍威龍 | 0 | 0 | 2 | 0 | 3.00 |
Longeveron has a consensus target price of $13.25, suggesting a potential upside of 231.25%.
Longeveron的共識目標價為13.25美元,暗示潛在上漲231.25%。
Institutional and Insider Ownership
機構和內部人持股
2.1% of Longeveron shares are owned by institutional investors. 41.6% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
2.1%的Longeveron股票由機構投資者持有。Longeveron 41.6%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、對衝基金和捐贈基金相信,一家公司有望實現長期增長。
Valuation and Earnings
估值和收益
This table compares VG Life Sciences and Longeveron's gross revenue, earnings per share (EPS) and valuation.
該表格比較了VG Life Science和Longeveron的毛收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
VG Life Sciences | N/A | N/A | N/A | N/A | N/A |
Longeveron | $1.31 million | 64.09 | -$17.05 million | ($0.89) | -4.49 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
VG生命科學 | 不適用 | 不適用 | 不適用 | 不適用 | 不適用 |
龍威龍 | 131萬美元 | 64.09 | -1,705萬美元 | ($0.89) | -4.49 |
VG Life Sciences has higher earnings, but lower revenue than Longeveron.
VG生命科學的收益高於Longeveron,但營收低於Longeveron。
About VG Life Sciences
關於VG生命科學
(Get Rating)
(獲取評級)
VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.
VG生命科學公司是一家生物技術公司,研究和開發一系列變革性療法,用於對抗癌症、傳染病和由慢性炎症引起的自身免疫性疾病。它提供了一種解決方案VG1177,它部署了一種合成肽,利用其優越的結合能力來消除不需要的II類相關不變鏈肽(CLIP),這種肽顯示在導致慢性炎症的特定B細胞上。該公司還提供代謝幹擾技術(MDT)化合物,通過擾亂癌細胞用於生存的代謝策略來阻止腫瘤細胞對治療敏感;以及羥氯喹,這是一種MDT化合物,可與其他抗癌藥物聯合用於治療耐藥癌症。此外,它還提供靶向多肽技術(TPT),這是一種消除促炎免疫細胞亞羣的技術,併為自身免疫和傳染病提供了一種可能的治療方法。VG Life Science Inc.前身為Virus Genetics Inc.,2012年11月更名為VG Life Science Inc.。該公司成立於1995年,總部設在加利福尼亞州聖巴巴拉。VG生命科學公司是Feelux Co.,Ltd.的子公司。
About Longeveron
關於龍威龍
(Get Rating)
(獲取評級)
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Longeveron Inc.是一家臨牀階段生物技術公司,開發針對衰老相關和危及生命的疾病的細胞療法。該公司的主要研究產品是LOMECEL-B,這是一種基於細胞的治療產品,來自培養擴增的藥物信號細胞,這些細胞來自年輕健康的成年捐贈者的骨髓。它正在進行各種適應症的第一階段和第二階段臨牀試驗,如衰老虛弱、阿爾茨海默病、代謝綜合徵、急性呼吸窘迫綜合徵和左心發育不良綜合徵。該公司成立於2014年,總部設在佛羅裏達州邁阿密。
Receive News & Ratings for VG Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VG Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受VG生命科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對VG生命科學和相關公司的最新新聞和分析師評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧